• Opus Genetics expects its current cash runway to extend into 2029, funding five clinical programs through multiple critical milestones.
• Four clinical data readouts are expected in 2027, with BEST1 pivotal trial dosing scheduled to begin in the second half.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.